Evidence map›Paper›PMID 34230894›Full record

ArticleACS central science2021

Discovery of Cyclic Peptide Ligands to the SARS-CoV-2 Spike Protein Using mRNA Display.

Alexander Norman, Charlotte Franck, Mary Christie, Paige M E Hawkins, Karishma Patel, Anneliese S Ashhurst, Anupriya Aggarwal, Jason K K Low, Rezwan Siddiquee, Caroline L Ashley and 6 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS central science, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
4.3field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 76 citations in OpenAlex.

  1. Article
  2. Phage Display as a Promising Platform for Peptide Drug Discovery.Pharmaceuticals (Basel, Switzerland) · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Peptide foldamer-based inhibitors of the SARS-CoV-2 S protein-human ACE2 interaction.Journal of enzyme inhibition and medicinal chemistry · 2023
    Article
  15. Article
  16. Review
  17. Article
  18. A broad-spectrum macrocyclic peptide inhibitor of the SARS-CoV-2 spike protein.Proceedings of the National Academy of Sciences of the United States of America · 2023
    Article
  19. Tyrosinase-Catalyzed Peptide Macrocyclization for mRNA Display.Journal of the American Chemical Society · 2023
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 1 institution in 1 country.

Alexander NormanSchool of Chemistry, The University of Sydney, Sydney, New South Wales 2006, Australia.
Charlotte FranckSchool of Chemistry, The University of Sydney, Sydney, New South Wales 2006, Australia.
Mary ChristieSchool of Life and Environmental Sciences, The University of Sydney, Sydney, New South Wales 2006, Australia.
Paige M E HawkinsSchool of Chemistry, The University of Sydney, Sydney, New South Wales 2006, Australia.
Karishma PatelSchool of Life and Environmental Sciences, The University of Sydney, Sydney, New South Wales 2006, Australia.
Anneliese S AshhurstSchool of Chemistry, The University of Sydney, Sydney, New South Wales 2006, Australia.
Anupriya AggarwalKirby Institute, Sydney, New South Wales 2052, Australia.
Jason K K LowSchool of Life and Environmental Sciences, The University of Sydney, Sydney, New South Wales 2006, Australia.
Rezwan SiddiqueeSchool of Life and Environmental Sciences, The University of Sydney, Sydney, New South Wales 2006, Australia.
Caroline L AshleySchool of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales 2006, Australia.
Megan SteainSchool of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales 2006, Australia.
James A TriccasSchool of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales 2006, Australia.
Stuart TurvilleKirby Institute, Sydney, New South Wales 2052, Australia.
Joel P MackaySchool of Life and Environmental Sciences, The University of Sydney, Sydney, New South Wales 2006, Australia.
Toby PassiouraSchool of Chemistry, The University of Sydney, Sydney, New South Wales 2006, Australia.ORCID https://orcid.org/0000-0002-6089-5067
Richard J PayneSchool of Chemistry, The University of Sydney, Sydney, New South Wales 2006, Australia.ORCID https://orcid.org/0000-0002-3618-9226
The University of Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The COVID-19 pandemic, caused by SARS-CoV-2, has led to substantial morbidity, mortality, and disruption globally. Cellular entry of SARS-CoV-2 is mediated by the viral spike protein, and affinity ligands to this surface protein have the potential for applications as antivirals and diagnostic reagents. Here, we describe the affinity selection of cyclic peptide ligands to the SARS-CoV-2 spike protein receptor binding domain (RBD) from three distinct libraries (in excess of a trillion molecules each) by mRNA display. We identified six high affinity molecules with dissociation constants (

Identifiers

PMID34230894
PMCPMC8189037
OpenAlexW3172318947

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.